becton dickinson compani
summari updat model base view
demand lutonix paclitaxel-co devic treat
peripher arteri diseas pad neg impact
fda issu letter healthcar provid recommend use
altern treatment paclitaxel-co devic fda letter
base agenc preliminari analysi long-term data
suggest potenti increas mortal risk patient treat
paclitaxel-co product fda expect conven
advisori committe meet mid-jun discuss data
next step outcom potenti impact adcom
unknown lower sale forecast
impli underli sale growth near
low-end guidanc bottom-lin lower
ep estim low-end bdx
guidanc assum declin lutonix
sale partli off-set increas sale altern product
addit launch everlinq creat av fistula covera
open av fistula venovo treat iliofemor venou
occlus diseas could also help provid off-set
lower lutonix sale forecast base march
updat fda letter lower sale forecast lutonix
assum reduct use sfa superfici femor arteri
us ou assum lutonix use av access
less affect forecast sale remain flattish final
pend btk below-the-kne indic believ fda approv
later year uncertain also lower btk sale
go forward aggreg lower revenu
nearli year
thereaft figur impact top- bottom-lin
less year beyond
fda recommend altern paclitaxel-co devic
paclitaxel-co balloons/st
gener use patient least addit analysi
safeti signal perform recommend
base fda complet preliminari analysi long-term
follow-up data pivot pre-market random trial
paclitaxel-co product indic pad identifi
potenti concern signal
mortal patient treat paclitaxel-co product
addit detail
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
includ bcr acquisit start ep calcul use two method
determin impact prefer convert as-convert
compani data secur llc estim reuter
figur chang forecast
price target nc
mm except av ww revenu growth ex-fx adjust compani report secur llc estim becton dickinson compani
price target base blend ev/ebitda ebitda price-to-earnings
estim risk includ slower expect integr bcr lower expect cost save
accret bcr unexpect delay debt pay unexpect pipelin delay/setback
believ well posit acceler top- bottom-lin growth bcr acquisit
potenti upsid
global medic devic compani oper two key segment medic life
scienc pend bcr acquisit add third leg platform intervent grew
revenu nearli pro forma underli basi
